Magazine Article | March 7, 2018

Companies To Watch: AmpliPhi Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Pushing bacteriophage therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

SNAPSHOT
AmpliPhi is developing bacteriophage (bacteria- killing viruses) as a new class of antibacterials. It has completed Phase 1 studies of a threephage product, coded AB-SA01, for treating multi-drug resistant (MDR) S. aureus infections, and a four-phage product, coded AB-PA01, is in preclinicals for treatment of P. aeruginosa infections, including MDR strains.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: